Ophthalmologists are struggling to obtain a biologic to treat macular degeneration, and some insurers are allegedly promoting off-label use of biosimilars for patients.
Ophthalmologists are struggling to obtain a biologic to treat macular degeneration, and some insurers are allegedly promoting off-label use of biosimilars for patients.
Copyright © 2024 | WordPress Theme by MH Themes